Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $14.80, but opened at $13.83. Adlai Nortye shares last traded at $13.83, with a volume of 444 shares.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Adlai Nortye in a research note on Friday, January 12th.
Get Our Latest Stock Report on ANL
Adlai Nortye Stock Down 6.8 %
The business's 50 day moving average price is $9.60 and its 200-day moving average price is $9.34.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. boosted its stake in Adlai Nortye Ltd. (NASDAQ:ANL - Free Report) by 128.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company's stock after purchasing an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned approximately 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 35.21% of the company's stock.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Recommended Stories
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
